Candida
12
2
2
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis
Phylogenetic Characteristics of Different Candida Species and Their Impact on the Clinical Picture of Patients With Invasive Candidiasis. What Has Changed During the COVID Pandemic?
Diagnostic Performance of the CandID PLUS PCR for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients
Candida PCR Diagnosis Strategy in Patients From Intensive Care Units
A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study
Early Diagnosis of Candidiasis in Premature Infants
Changing Patterns of Candida Infections in Urban Medical Centers
Antimicrobial Photodynamic Therapy Associated With the Conventional Endodontic Treatment: A Clinical and Microbiological Study
Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility
An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates
Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients
Anidulafungin Versus Fluconazole in the Treatment of Candidemia